Biel Clovis Tablet (Clopidogrel Hydrogen Sulfate)

Adult dose

○ Adults 1. In patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. In patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), on the day treatment with this medicine is initiated, start with a loading dose of 300 mg once daily, followed by a maintenance dose of 75 mg orally once daily. Aspirin 75 ～ 325 mg should be coadministered with this medicine once daily. 3. In patients with atrial fibrillation, administer this medicine 75 mg orally once daily. Aspirin 75 ～ 100 mg should be coadministered with this medicine once daily. ○ Patients with renal impairment : Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment : Treatment experience in patients with moderate hepatic disease and bleeding diathesis is limited. This medicine may be administered with or without food.

This medication inhibits platelet aggregation in the blood to prevent thrombus formation. Patients who have genetically diminished function of a specific enzyme (CYP2C19) may experience reduced effectiveness of this medication; in such cases, alternative treatments should be considered. Concomitant use of this medication with drugs that increase enzyme activity may enhance the risk of bleeding, so such combinations should be avoided. Patients with allergies to this medication or its components, those with bleeding disorders, severe liver damage, pregnant women, and those with lactose intolerance should not take this medication. Patients at high risk of bleeding or those scheduled for surgery should exercise caution when taking this medication and it is recommended to discontinue use 5-7 days prior to surgery. This medication may increase the risk of bleeding, so any bleeding symptoms should be reported to a physician immediately. Care should be taken as the risk of bleeding may be higher when used in combination with other antiplatelet agents, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), and selective serotonin reuptake inhibitors (SSRIs). Rarely, this medication may cause a serious blood disorder known as Thrombotic Thrombocytopenic Purpura (TTP), so patients should inform their healthcare professional immediately if they experience thrombocytopenia or signs of bleeding. During pregnancy, the risk to the fetus is low, but caution is warranted due to bleeding risks during delivery, and nursing mothers should consult a healthcare professional before use. Elderly patients or those with impaired renal or liver function may be at increased risk for bleeding and may require dose adjustments and close monitoring. In case of overdose, bleeding time may be prolonged and bleeding complications may occur, so adherence to prescribed dosage is crucial, and platelet transfusion may be necessary to reverse the effect if required. This medicine should be kept out of reach of children and should not be transferred to other containers.

• Hemorrhage
• gastrointestinal bleeding
• purpura
• contusion
• hematoma
• epistaxis
• hematoma
• hematuria
• intraocular hemorrhage
• intracranial hemorrhage

This medication must be stored in a tightly closed container to protect it from exposure to air and humidity. It is important to maintain storage temperatures between 1 and 30 degrees Celsius at room temperature.

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle